ReviewThe lancet. Diabetes & endocrinology2015
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.
Review in The lancet. Diabetes & endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03361098 (Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- The effects of Panax notoginseng for the treatment of diabetic nephropathy in animals: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Preclinical evidence of ginkgo biloba extract on diabetic nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.African health sciences · 2022 · on this mapPooled it
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.Diabetes, obesity & metabolism · 2020Trial
- Plasma uric acid and renal haemodynamics in type 2 diabetes patients.Nephrology (Carlton, Vic.) · 2020Trial
- Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.Diabetes, obesity & metabolism · 2019 · on this mapTrial
- Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.Diabetes, obesity & metabolism · 2018Trial
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.Diabetologia · 2016Trial
- Trial
- Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Incretin and glucagon receptor polypharmacology in chronic kidney disease.American journal of physiology. Endocrinology and metabolism · 2024Review
- Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update.Biomedicines · 2023Review
- Nomogram-Based Chronic Kidney Disease Prediction Model for Type 1 Diabetes Mellitus Patients Using Routine Pathological Data.Journal of personalized medicine · 2022Article
- Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial.Clinical diabetes and endocrinology · 2022Article
- GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes.Journal of clinical medicine · 2021Review
- Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross-sectional study.Microcirculation (New York, N.Y. : 1994) · 2021Article
- Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.Advances in chronic kidney disease · 2021 · on this mapReview
- Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.Nephrology (Carlton, Vic.) · 2021Review
- Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes.Diabetes care · 2021Article
- SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.Journal of human hypertension · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In parallel with the type 2 diabetes pandemic, diabetic kidney disease has become the leading cause of end-stage renal disease worldwide, and is associated with high cardiovascular morbidity and mortality. As established in landmark randomised trials and recommended in clinical guidelines, prevention and treatment of diabetic kidney disease focuses on control of the two main renal risk factors, hyperglycaemia and systemic hypertension. Treatment of systemic hypertension with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers is advocated because these drugs seem to exert specific renoprotective effects beyond blood pressure lowering. Emerging evidence shows that obesity, glomerular hyperfiltration, albuminuria, and dyslipidaemia might also adversely affect the kidney in diabetes. Control of these risk factors could have additional benefits on renal outcome in patients with type 2 diabetes. However, despite multifactorial treatment approaches, residual risk for the development and progression of diabetic kidney disease in patients with type 2 diabetes remains, and novel strategies or therapies to treat the disease are urgently needed. Several drugs used in the treatment of type 2 diabetes are associated with pleiotropic effects that could favourably or unfavourably change patients' renal risk profile. We review the risk factors and treatment of diabetic kidney disease, and describe the pleiotropic effects of widely used drugs in type 2 diabetes management on renal outcomes, with special emphasis on antihyperglycaemic drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.